[BMJ] KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy |
|
This post will be closed automatically in 2026-08-17 16:26
Best Answer
2026-8-14
|
| |
10
Multifocal fixed drug eruption temporally associated with sitagliptin therapy in type 2 diabetes mellitus
10
E-twenty-six-specific sequence variant 5 (ETV5) facilitates hepatocellular carcinoma progression and metastasis through enhancing polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC)-mediated immunosuppression
10
Diagnosis and management of acute hyperkalaemia
10
Practical Prescribing: Aspirin
10
Obesity management requires a personalised, collaborative approach from general practice
